Valuation: Convatec Group Plc

Market Cap 5.63B 4.96B 4.7B 4.24B 7.99B 540B 8.1B 56.21B 21.63B 276B 21.14B 20.68B 885B P/E 2026 *
22.3x
P/E 2027 * 15.3x
Enterprise Value 7.03B 6.19B 5.87B 5.3B 9.98B 674B 10.11B 70.21B 27.02B 345B 26.41B 25.83B 1,105B EV / Sales 2026 *
2.75x
EV / Sales 2027 * 2.51x
Free-Float
95.09%
Yield 2026 *
2.76%
Yield 2027 * 3.15%
Manager TitleAgeSince
Chief Executive Officer 62 03/08/2025
Director of Finance/CFO 51 03/08/2025
Chief Operating Officer - 31/05/2026
Director TitleAgeSince
Director/Board Member 71 13/08/2017
Chairman 78 29/09/2019
Director/Board Member 62 01/03/2020
Change 5-day change 1-year change 3-year change Capi.($)
-4.29%-.--% - - 5.63B
-1.15%-3.61%-27.01%+1.77% 171B
-0.21%-2.98%-9.43%+10.42% 110B
-0.87%+0.93%-25.24%-0.58% 106B
-0.69%-0.07%-47.78%-11.65% 75.99B
+1.69%-1.60%-2.20%+70.27% 57.3B
-0.32%-0.74%-6.83%-30.98% 48.76B
+3.44%+7.90%+19.12%+59.15% 50.19B
-0.04%+1.55%-15.93%+20.98% 41.14B
-0.01%-1.51%+30.37%-8.88% 32.56B
Average -0.23%-1.46%-9.44%+12.28% 77B
Weighted average by Cap. -0.17%-2.07%-16.05%+9.47%

Financials

2026 *2027 *
Net sales 2.55B 2.25B 2.13B 1.92B 3.63B 245B 3.67B 25.5B 9.81B 125B 9.59B 9.38B 401B 2.73B 2.41B 2.28B 2.06B 3.88B 262B 3.93B 27.28B 10.5B 134B 10.26B 10.04B 430B
Net income 250M 220M 208M 188M 355M 23.96B 359M 2.49B 960M 12.25B 938M 918M 39.27B 364M 321M 304M 274M 517M 34.93B 524M 3.64B 1.4B 17.86B 1.37B 1.34B 57.26B
Net Debt 1.4B 1.24B 1.17B 1.06B 1.99B 134B 2.02B 14B 5.39B 68.75B 5.27B 5.15B 220B 1.22B 1.08B 1.02B 922M 1.74B 117B 1.76B 12.22B 4.7B 59.98B 4.6B 4.49B 192B
Logo Convatec Group Plc
ConvaTec Group Plc specializes in the development, manufacturing and marketing of medical devices and products for ostomy care, wound care, and incontinence. The group also offers perfusion devices. Net sales break down by area of activity as follows: - wound care (30.9%): antimicrobial dressings, occlusive dressings, compression bandages, etc.; - ostomy care (27.7%): skin barriers, one-piece bags, 2-piece appliance bags, urostomy bags, etc.; - incontinence care (22%); - infusion (19.4%). At the end of 2025, the group operated 7 production sites worldwide. Net sales are distributed geographically as follows: Europe (29.6%), North Americas (55.7%) and other (14.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA